Radisys Corporation (NASDAQ:RSYS) tinted gains of +3.36% (+0.02 points) to US$0.77. The volume of 0.19 Million shares climbed down over an trading activity of 441.46 Million shares. EPS ratio determined by looking at last 12 month figures is -0.38. Over the same time span, the stock marked US$4 as its best level and the lowest price reached was US$0.53. The corporation has a market cap of US$30.15 Million.

Radisys Corporation (NASDAQ:RSYS)’s earnings per share has been growing at a 21.8 percent rate over the past 5 year when average revenue increase was noted as -14.1 percent. The return on equity ratio or ROE stands at -271 percent while most common profitability ratio return on investment (ROI) was -71.6 percent. The company’s institutional ownership is monitored at 38.9 percent. The company’s net profit margin has achieved the current level of -40.1 percent and possesses 16 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.33. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

resTORbio, Inc. (NASDAQ:TORC) is worth US$297.33 Million and has recently risen 3.33% to US$10.54. The latest exchange of 0.13 Million shares is below its average trading activity of 141.75 Million shares. The day began at US$10.26 but the price moved to US$10.07 at one point during the trading and finally capitulating to a session high of US$10.67. The stock tapped a 52-week high of US$21.1 while the mean 12-month price target for the shares is US$28.75.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 1.74, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 41.7%, it carries an earnings per share ratio of -2.18.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 3 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.25.